THRB and breast carcinoma: In particular, aberrant TRs that act as dominant-negative inhibitors of wild-type TR activity have been found in more than 70% of human hepatocellular carcinomas [15]–[18], and biallelic inactivation of TRβ by promoter methylation as well as mutations in this gene are also frequent in breast cancers [19], [20].